The landmark Alzheimer's Disease Neuroimaging Initiative (ADNI) began in October 2004 with a goal of finding more sensitive and accurate methods to detect Alzheimer's disease.... Read More
Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, publis.... Read More